An anonymous director reports
THERATECHNOLOGIES INC.: SHORT SUPPLY OF EGRIFTA(R) ANNOUNCED
Theratechnologies Inc. expects current inventory of Egrifta (tesamorelin for injection) to be depleted in the coming weeks due to a combination of manufacturing delays and issues observed during the production of new batches of Egrifta. The depletion of the inventory will result in a shortage of Egrifta and an eventual stock out. EMD Serono Inc. has notified the United States Food and Drug Administration about this product shortage.
The company also announced that it has made the decision to temporarily cease the manufacture of Egrifta. At this time, the company is unable to determine a timeline to resume the manufacture and delivery of Egrifta and the company is currently investigating the causes of the issues observed. The company will update the market when new information is available.
The transaction with EMD Serono, previously announced on Dec. 13, 2013, relating to the company regaining all rights to Egrifta in the United States, is still expected to close during the company's second quarter of its current fiscal year, despite the decision made by the company to temporarily halt the manufacture of Egrifta.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.